Every material Form 8-K Vor Biopharma Inc. has filed with the SEC since March 27, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Vor Biopharma director Andrew Levin resigned from the board effective immediately on July 6, 2026, and the company said the resignation was not due to any disagreement. On July 7, 2026, the board appointed David Zaccardelli, Pharm.D., a former pharmaceutical chief executive, to fill the vacancy as an independent Class II director. The change is a board-level administrative update with no stated effect on operations or financial results.
Andrew Levin, M.D., Ph.D. resigned as a director effective immediately; notice delivered July 6, 2026
David Zaccardelli, Pharm.D., 61, appointed July 7, 2026 as an independent Class II director, serving until the 2029 annual meeting
Zaccardelli receives a $40,000 annual cash retainer and an initial option grant of up to 68,000 shares or $700,000 in grant-date value, whichever is lower
Vor Bio announced that China's National Medicinal Products Administration granted conditional approval of telitacicept for adult IgA nephropathy and approval for adult Sjögren's disease, both in China, where partner RemeGen holds development and commercialization rights. Vor Bio holds exclusive rights outside Greater China, so the filing signals progress on the drug's global program but no direct financial figures are disclosed.
NMPA conditionally approved telitacicept for adult IgA nephropathy in China, per Exhibit 99.1.
NMPA approved telitacicept for adult Sjögren's disease in China, per Exhibit 99.2.
In the Phase 3 TELIGAN trial, telitacicept 240 mg produced a 55% placebo-adjusted reduction in UPCR at Week 39.
RemeGen runs development and commercialization in China; Vor Bio holds rights outside Greater China.
On March 26, 2026, Vor Bio agreed to sell 5,338,078 common shares at $14.05 each, for gross proceeds of approximately $75.0 million, to entities affiliated with TCGX. Closing is expected March 30, 2026, and the company will have 54,185,582 shares outstanding afterward, so existing shareholders will hold a smaller percentage of the company. The company plans to use the net proceeds to advance its clinical pipeline and for general corporate purposes.
5,338,078 shares sold at $14.05 per share, for gross proceeds of approximately $75.0 million
Closing expected March 30, 2026; 54,185,582 shares of common stock outstanding after closing
Proceeds to advance clinical development of telitacicept, including Phase 3 trials in myasthenia gravis and primary Sjögren's disease, and for general corporate purposes
Registration statement on Form S-3 to cover resales due within 30 days of closing, with liquidated damages if deadlines are missed
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Vor Biopharma Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →